1246749-89-2

Upstream product

• 201849-15-2 2-bromo-1-chloro-4-fluoro-benzene 
• 1246749-84-7 tert-butyl 5-[2-chloro-5-fluorophenyl]hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 1246749-88-1 C₁₆H₁₅ClFN₇O 
• 1246749-60-9 3-[5-(2-chloro-5-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]isoxazole-5-carboxamide 
• 1246749-86-9 3-[5-(2-chloro-5-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4,5-dihydroisoxazole-5-carboxamide 
• 1246749-85-8 C₁₂H₁₄ClFN₂*ClH 
• 141449-85-6 tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1246749-88-1 2-(2-chloro-5-fluorophenyl)-5-[5-(2H-tetrazol-5-yl)isoxazol-3-yl]octahydropyrrolo[3,4-c]pyrrole 

Downstream Products

• 1246748-94-6 (5-{3-[5-(2-chloro-5-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]isoxazol-5-yl}-2H-tetrazol-2-yl)acetic acid 

Relevant academic research and scientific papers

Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series

Inhibition of stearoyl-CoA desaturase (SCD) activity represents a potential novel mechanism for the treatment of metabolic disorders including obesity and type II diabetes. To circumvent skin and eye adverse events observed in rodents with systemically-distributed SCD inhibitors, our research efforts have been focused on the search for new and structurally diverse liver-targeted SCD inhibitors. This work has led to the discovery of novel, potent and structurally diverse liver-targeted bispyrrolidine SCD inhibitors. These compounds possess suitable cellular activity and pharmacokinetic properties to inhibit liver SCD activity in a mouse pharmacodynamic model.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver steatosis; and non-alcoholic steatohepatitis.